selected publications
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.
American journal of hematology.
2020
Academic Article
GET IT
Times cited: 5 -
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
American journal of hematology.
2019
Academic Article
GET IT
Times cited: 4 -
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Blood advances.
2019
Academic Article
GET IT
Times cited: 12 -
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
American journal of hematology.
2019
Academic Article
GET IT
Times cited: 2 -
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.
Leukemia & lymphoma.
2019
Article
GET IT
Times cited: 2 -
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.
Leukemia & lymphoma.
2018
Academic Article
GET IT
Times cited: 4 -
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
Leukemia & lymphoma.
2018
Academic Article
GET IT
Times cited: 9 -
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.
Cancer research.
2018
Academic Article
GET IT
Times cited: 69 -
Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.
PLoS genetics.
2018
Academic Article
GET IT
Times cited: 31 -
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 18 -
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Clinical lymphoma, myeloma & leukemia.
2017
Academic Article
GET IT
Times cited: 7 -
IgM myeloma: A multicenter retrospective study of 134 patients.
American journal of hematology.
2017
Academic Article
GET IT
Times cited: 20 -
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.
The Journal of clinical investigation.
2017
Academic Article
GET IT
Times cited: 9 -
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Academic Article
GET IT
Times cited: 7 -
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
British journal of haematology.
2016
Academic Article
GET IT
Times cited: 14 -
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 49 -
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Leukemia & lymphoma.
2014
Academic Article
GET IT
Times cited: 7 -
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Academic Article
GET IT
Times cited: 20 -
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Blood.
2013
Academic Article
GET IT
Times cited: 32 -
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Blood.
2012
Academic Article
GET IT
Times cited: 74 -
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 90 -
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
American journal of hematology.
2010
Academic Article
GET IT
Times cited: 46 -
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
Cancer immunity.
2010
Academic Article
GET IT
Times cited: 41 -
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.
Journal of immunology (Baltimore, Md. : 1950).
2009
Academic Article
GET IT
Times cited: 30 -
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
British journal of haematology.
2008
Academic Article
GET IT
Times cited: 52 -
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2008
Academic Article
GET IT
Times cited: 104 -
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Leukemia & lymphoma.
2007
Academic Article
GET IT
Times cited: 53 -
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood.
2007
Academic Article
GET IT
Times cited: 161 -
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 79